Cell Therapies Pty Ltd Company Profile

06:09 EDT 24th March 2018 | BioPortfolio

Cell Therapies Pty Ltd is in the business of planning and conducting clinical trials that involve the collection, manipulation and storage of blood cells and human tissue. The services range from laboratory rental through to fully-integrated planning and execution of clinical trials that involve cellular therapeutics manufactured in code of Good Manufacturing Practice (cGMP) and Therapeutic Goods Administration (TGA) licensed facilities.


105 Highgrove Drive
Chapel Hill
North Carolina
United States of America


Phone: (919) 969 1130

News Articles [1551 Associated News Articles listed on BioPortfolio]

FDA Sets Path for Stem Cell Therapies

(CNN) – Just months after the US Food and Drug Administration announced efforts to crack down on stem cell clinics touting unapproved therapies, the agency now plans to help expedite the develop...

How Durable Are CAR T-Cell Therapies?

The use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of hematologic malignancies is still in its early stages, but when the FDA approved tisagenlecleucel and axicabtagene cilo...

Regulatory approvals and innovation drives: Cell therapies come of age

Cell therapies have reached their 'teenage years' and must now overcome processing efficiencies and quality struggles, say industry delegates.

Czech this Biotech Out! Bioinova Develops Stem Cell Therapies

This week, we are in Prague to visit Bioinova. This biotech develops cell therapies for a wide range of indications, from broken bones to autoimmune diseases. Mission: From bone marrow and adipose (f...

Commission demands reform on experimental cell therapies

The reputation of stem cell research is being undermined by unscrupulous clinics offering unproven therapies, says a report published last week...

TCR² Raises $125M to Move Ahead with Its Cell Therapy, CAR-T’s Cousin

TCR² Therapeutics has raised a $125 million Series B round to push ahead with live, cancer-fighting T cells. T cell receptor (TCR) therapies, the firm’s area of focus, have not progressed as far as...

Cell and gene therapies offer promise, but face market access challenges

In light of the progress and potential of cell and gene therapies, Amy Grogg, senior vice president of…

2017: The dawning of cell and gene therapies

Product approvals and a regulatory focus on regenerative medicines has made 2017 a breakthrough year for cell and gene therapies, say consultants.

Drugs and Medications [36 Associated Drugs and Medications listed on BioPortfolio]

Cladribine [Onco Therapies Limited ]

Cladribine Injection

Zolinza [Merck Sharp & Dohme Corp.]

These highlights do not include all the information needed to use ZOLINZA safely and effectively. See full prescribing information for ZOLINZA. ZOLINZA® (vorinostat) CapsulesInitial U.S. Approval: 20...

Humira [Abbott Laboratories]

These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA.HUMIRA (adalimumab) Injection, Solution for Subcutaneous us...

Sun care [Zenith Medicosm SL]

Drug Facts

Sun care [Zenith Medicosm SL]

Drug Facts

PubMed Articles [3735 Associated PubMed Articles listed on BioPortfolio]

Chimeric Antigen Receptor T-Cell Therapy for Lymphomas.

It is estimated that 2.1% of the population of the United States will develop non-Hodgkin lymphoma (NHL) in a lifetime. With treatment, 71% of patients with NHL live to 5 years. Because current drugs ...

An engineered biomarker system to monitor and modulate immune clearance of cell therapies.

Cell transplants offer a new opportunity to deliver therapies with novel and complex mechanisms of action. Understanding the pharmacology of cell transplants is important to deliver this new therapy e...

Stem Cell Smart Technology, where are we now and how far we have to go?

Approximately eight million people in the United States have peripheral arterial disease, which increases exponentially with age. There have been a plethora of available treatments including surgery, ...

Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts.

Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah™ and Yescarta™) were recently approved by the FDA. Kymriah™ for the treatment of pediatric patients and young adults with...

Programming gene and engineered-cell therapies with synthetic biology.

Gene and engineered-cell therapies promise to treat diseases by genetically modifying cells to carry out therapeutic tasks. Although the field has had some success in treating monogenic disorders and ...

Clinical Trials [7162 Associated Clinical Trials listed on BioPortfolio]

Tracking Peripheral Blood Mononuclear Cells With Fluorine MRI

Cell-based therapies in the form of stem cell-based or immune cell-based therapies are becoming important treatment options that are either approved for clinical use or are showing promise...

Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer

Gene and cell therapies have a real value potential (example: potential long-term effect, curative potential, and single administration) but also drawbacks (example: treatment perceived as...

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

This will be a single arm, multi-site phase Ib/II clinical trial of standard doses of High Dose Interleukin-2 (HD IL2) (600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apar...

Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma

Treatment of Chronic Lymphocytic Leukemia

CLL is a disease of the elderly, identifying effective therapies with better toxicity profiles is thus a high priority, and targeted therapies may allow attainment of this goal.

Companies [1685 Associated Companies listed on BioPortfolio]

Beike Biotechnology Company Limited

Beike Biotechnology ( is Asia's leading biotechnology company focusing on adult stem cell therapies. Beike's scientists have been focused on the development and commerc...

Beike Biotechnology Co. Ltd.

Beike Biotechnology ( ) is China's leading biotechnology company focusing on adult stem cell therapies. Beike's scientists have been focused on the development and comme...

Opexa Therapeutics

Opexa Therapeutics is a commercialization driven biotechnology cellular therapy company that develops autologous personalized cell therapies for the treatment of various diseases. The Company is focus...

WuXi AppTec

WuXi AppTec’s U.S. Manufacturing and Testing group provides a comprehensive range of integrated programs for biologics, advanced therapies and medical devices – along wi...

U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell...

More Information about "Cell Therapies Pty Ltd" on BioPortfolio

We have published hundreds of Cell Therapies Pty Ltd news stories on BioPortfolio along with dozens of Cell Therapies Pty Ltd Clinical Trials and PubMed Articles about Cell Therapies Pty Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cell Therapies Pty Ltd Companies in our database. You can also find out about relevant Cell Therapies Pty Ltd Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record